 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Test data exclusivity" – news ·newspapers ·books ·scholar ·JSTOR(December 2023) (Learn how and when to remove this message) |
Test data exclusivity refers to protection ofclinical trial data required to be submitted to aregulatory agency to prove safety and efficacy of a newdrug, and prevention ofgeneric drug manufacturers from relying on this data in their own applications. It provides a form of market exclusivity outside that provided bypatent rights.[1][2]
Pharmaceutical companies argue that since test data is so expensive to produce, it is an unfair advantage to let other companies rely on that data without cost. Critics charge that it can act as a restriction to producing a generic copy; that although it would not raise prices of drugs, it would prevent prices from falling due to generic competition; and make it more costly for the poor to gain access to life-saving drugs (e.g. anti-HIV & anti-malarial medications.) Developed countries with innovative pharmaceutical industries (including the United States) have sought data exclusivity provisions in Free Trade Agreements with their trading partners, e.g.DR-CAFTA which includes such a provision.[3]
According to theEuropean Commission:
One critical issue in this regard is the issue of data exclusivity for pioneer drug companies (pharmaceutical R&D organizations). From the standpoint of economics, industries where the R&D process is costly and risky need longer exclusivity periods to realize innovation benefits, compared to those industries where innovation is easier and less costly.
Some academics allege that pharmaceutical data exclusivity protection unfairly restricts the rapid public dispersal of knowledge that is supposed to be the trade-off for a grant of a patent orintellectual monopoly privilege.[5] They allege that data exclusivity is really a form ofevergreening pharmaceutical patent protection that may even restrict the capacity of governments to benefit from the granting of acompulsory license on the patents on a medicine, since the data monopoly will still prevent the marketing of generic products, even though the patent licenses have been granted by the government or a court.[5]
A separate criticism of data exclusivity concerns medical and research ethics. Specifically, it is considered unethical under theDeclaration of Helsinki to undertake duplicative clinical trials on human subjects. Similar concerns have been raised in the context of testdata protection for certain agricultural or cosmetic products, leading in some countries to proposals for cost sharing rather than exclusive rights as the form of test data protection.